Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02028884
Recruitment Status : Active, not recruiting
First Posted : January 7, 2014
Last Update Posted : December 20, 2019
Chugai Pharmaceutical
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 6, 2018
Estimated Study Completion Date : March 31, 2021
Certification/Extension First Submitted : June 5, 2019